These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

385 related items for PubMed ID: 9042987

  • 21. African American ethnicity is not associated with development of Barrett's oesophagus after erosive oesophagitis.
    Alkaddour A, McGaw C, Hritani R, Palacio C, Nakshabendi R, Munoz JC, Vega KJ.
    Dig Liver Dis; 2015 Oct; 47(10):853-6. PubMed ID: 26188839
    [Abstract] [Full Text] [Related]

  • 22.
    Swedish Council on Health Technology Assessment.
    ; 2007 10. PubMed ID: 28876800
    [Abstract] [Full Text] [Related]

  • 23. The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism.
    Kawamura M, Ohara S, Koike T, Iijima K, Suzuki J, Kayaba S, Noguchi K, Hamada S, Noguchi M, Shimosegawa T, Study Group of GERD.
    Aliment Pharmacol Ther; 2003 Apr 01; 17(7):965-73. PubMed ID: 12656699
    [Abstract] [Full Text] [Related]

  • 24. Increased acid and bile reflux in Barrett's esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy.
    Menges M, Müller M, Zeitz M.
    Am J Gastroenterol; 2001 Feb 01; 96(2):331-7. PubMed ID: 11232672
    [Abstract] [Full Text] [Related]

  • 25. Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis.
    Richter JE, Kovacs TO, Greski-Rose PA, Huang section sign B, Fisher R.
    Aliment Pharmacol Ther; 1999 Jun 01; 13(6):795-804. PubMed ID: 10383510
    [Abstract] [Full Text] [Related]

  • 26. Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus.
    Sampliner RE.
    Am J Gastroenterol; 1994 Oct 01; 89(10):1844-8. PubMed ID: 7942680
    [Abstract] [Full Text] [Related]

  • 27. Young patients with Barrett's oesophagus experience less reflux complaints.
    Loffeld RJ.
    Digestion; 2001 Oct 01; 64(3):151-4. PubMed ID: 11786662
    [Abstract] [Full Text] [Related]

  • 28. Acid suppression in the long-term treatment of peptic stricture and Barrett's oesophagus.
    Lundell L.
    Digestion; 1992 Oct 01; 51 Suppl 1():49-58. PubMed ID: 1356869
    [Abstract] [Full Text] [Related]

  • 29. Comparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive oesophagitis: a randomized, active-controlled, double-blind study.
    Kovacs TO, Wilcox CM, DeVault K, Miska D, Bochenek W, Pantoprozole US Gerd Study Group B.
    Aliment Pharmacol Ther; 2002 Dec 01; 16(12):2043-52. PubMed ID: 12452936
    [Abstract] [Full Text] [Related]

  • 30. Speed of onset of oesophageal acid reduction with different proton-pump inhibitors in patients with reflux oesophagitis.
    Newton M, Burnham WR, Kamm MA.
    Eur J Gastroenterol Hepatol; 1998 Sep 01; 10(9):753-8. PubMed ID: 9831269
    [Abstract] [Full Text] [Related]

  • 31. A double-blind, randomized comparison of omeprazole Multiple Unit Pellet System (MUPS) 20 mg, lansoprazole 30 mg and pantoprazole 40 mg in symptomatic reflux oesophagitis followed by 3 months of omeprazole MUPS maintenance treatment: a Dutch multicentre trial.
    Mulder CJ, Westerveld BD, Smit JM, Oudkerk Pool M, Otten MH, Tan TG, van Milligen de Wit AW, de Groot GH, Dutch omeprazole MUPS study group.
    Eur J Gastroenterol Hepatol; 2002 Jun 01; 14(6):649-56. PubMed ID: 12072599
    [Abstract] [Full Text] [Related]

  • 32. Esomeprazole: a review of its use in the management of acid-related disorders in the US.
    Scott LJ, Dunn CJ, Mallarkey G, Sharpe M.
    Drugs; 2002 Jun 01; 62(7):1091-118. PubMed ID: 11985491
    [Abstract] [Full Text] [Related]

  • 33. Lansoprazole 15 and 30 mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis.
    Hatlebakk JG, Berstad A.
    Aliment Pharmacol Ther; 1997 Apr 01; 11(2):365-72. PubMed ID: 9146777
    [Abstract] [Full Text] [Related]

  • 34. Lack of predictors of normalization of oesophageal acid exposure in Barrett's oesophagus.
    Wani S, Sampliner RE, Weston AP, Mathur S, Hall M, Higbee A, Sharma P.
    Aliment Pharmacol Ther; 2005 Oct 01; 22(7):627-33. PubMed ID: 16181302
    [Abstract] [Full Text] [Related]

  • 35. Effects of long-term treatment with proton pump inhibitors in gastro-oesophageal reflux disease on the histological findings in the lower oesophagus.
    Stolte M, Vieth M, Schmitz JM, Alexandridis T, Seifert E.
    Scand J Gastroenterol; 2000 Nov 01; 35(11):1125-30. PubMed ID: 11145281
    [Abstract] [Full Text] [Related]

  • 36. Lansoprazole in the treatment of reflux oesophagitis: a survey of clinical studies.
    Berstad A, Hatlebakk JG.
    Aliment Pharmacol Ther; 1993 Nov 01; 7 Suppl 1():34-6, discussion 61-6. PubMed ID: 8490077
    [Abstract] [Full Text] [Related]

  • 37. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group.
    Castell DO, Richter JE, Robinson M, Sontag SJ, Haber MM.
    Am J Gastroenterol; 1996 Sep 01; 91(9):1749-57. PubMed ID: 8792693
    [Abstract] [Full Text] [Related]

  • 38. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease.
    Richter JE, Campbell DR, Kahrilas PJ, Huang B, Fludas C.
    Arch Intern Med; 2000 Jun 26; 160(12):1803-9. PubMed ID: 10871974
    [Abstract] [Full Text] [Related]

  • 39. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
    Bytzer P, van Zanten SV, Mattsson H, Wernersson B.
    Aliment Pharmacol Ther; 2012 Oct 26; 36(7):635-43. PubMed ID: 22860764
    [Abstract] [Full Text] [Related]

  • 40. Risk of Barrett's oesophagus, oesophageal adenocarcinoma and reflux oesophagitis and the use of nitrates and asthma medications.
    Ladanchuk TC, Johnston BT, Murray LJ, Anderson LA, FINBAR study group.
    Scand J Gastroenterol; 2010 Dec 26; 45(12):1397-403. PubMed ID: 20626305
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.